Advertisement
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKS●NASDAQ
HealthcareBiotechnology
$43.38
$0.62(1.45%)
U.S. Market opens in 16h 8m
Advertisement

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap7.2B
P/E Ratio46.10
EPS (TTM)$0.90
ROE0.09%
Fundamental Analysis

AI Price Forecasts

1 Month$27.00
3 Months$27.57
1 Year Target$30.20

ALKS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alkermes plc (ALKS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 74.72, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $30.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 46.10 and a market capitalization of 7.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.45%
5-Day Change
8.45%
1-Month Change
26.95%
3-Month Change
48.16%
6-Month Change
48.05%
Year-to-Date (YTD) Change
55.04%
1-Year Change
37.54%
3-Year Change
47.25%
5-Year Change
87.95%
All-Time (Max) Change
688.73%

Contact Information

https://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, NaN, 4

Company Facts

1,800 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions